Agonist stimulation through TLR4 (using LPS) and/or TLR9 (using CpG) has been shown to reduce symptoms of diabetes, EAE, and arthritis in mice, while decreased TLR9 expression in humans leads to an increased incidence of systemic lupus erythematosus (22–25). Here, TLR9 is linked to arthritic joint disease.